Pfizer completes Phase III trials for male pattern baldness Treatment????!!!!!
- Thread starter jfhawk06
- Start date
DonaldAnderson
Experienced Member
- Reaction score
- 5
Props. Interesting indeed.
Private Ryan
Established Member
- Reaction score
- 2
may the God of hair answer our prayer.
G
Guest
Guest
I already posted a discussion about this under the New Research
topic
topic
G
Guest
Guest
Surprise attack by Pfizer
In this topic [ http://www.gourmetstylewellness.com/discussions ... hp?t=22538 ], someone says that this product is Kevis (http://www.kevis.com).
But this is false. I think Pfizer produced a whole new product together with its satellite company Anaderm. See: http://www.bioedonline.org/news/news.cfm?art=443
The FDA Clinical trials page says that Phase 3 has been completed this month.
This could be big news guys. A whole new hair product will most likely be hitting the market very soon. :!: :!: :!: :!:
In this topic [ http://www.gourmetstylewellness.com/discussions ... hp?t=22538 ], someone says that this product is Kevis (http://www.kevis.com).
But this is false. I think Pfizer produced a whole new product together with its satellite company Anaderm. See: http://www.bioedonline.org/news/news.cfm?art=443
The FDA Clinical trials page says that Phase 3 has been completed this month.
This could be big news guys. A whole new hair product will most likely be hitting the market very soon. :!: :!: :!: :!:
Britannia
Senior Member
- Reaction score
- 3
I heard a rumour (and I personally doubt it very much) that Pfizer paid off GSK to abandon there Dutasteride trials, because Pfizer had been working on a top secret DHT blasting topical. I heard this 6 months or so ago and laughed. But it seems a bit strange that Pfizer now claim to have a hair loss product in trials......
Dinzy I have an irrelevant question for you. Do you study in the University of Urbana? Because I am thinking to apply for a Graduate study there. If yes please tell me if its a village or a city because I do not want to make company to wolfs and bears 
)
Thanks
)Thanks
Dave001
Experienced Member
- Reaction score
- 0
Patents assigned to Pfizer with the word "alopecia" in any field (20 hits):
Execute query.
And indole derived 5 alpha-reductase inhibitor? Hopefully it isn't some form of systemic hormonal therapy. It would have to be locally active only to be of any value if it's a 5 alpha-reductase inhibitor. I suspect that the drug mentioned is one that has already been discussed ad nauseam, but maybe not.
I'm skeptical that it's a hormonally active treatment (even topical) because of the inclusion range of ages, 15-49.
Execute query.
And indole derived 5 alpha-reductase inhibitor? Hopefully it isn't some form of systemic hormonal therapy. It would have to be locally active only to be of any value if it's a 5 alpha-reductase inhibitor. I suspect that the drug mentioned is one that has already been discussed ad nauseam, but maybe not.
I'm skeptical that it's a hormonally active treatment (even topical) because of the inclusion range of ages, 15-49.
unluckystat
Member
- Reaction score
- 0
Britannia said:
A DHT blasting topical would be the best case scenario because it would not alter our DHT in our blood stream to dangerously low levels.
seekinghair
Member
- Reaction score
- 0
It might have something to do with this:
OSI Pharmaceuticals Concludes its Alliance with Anaderm and Pfizer; Continues to Focus on Oncology
MELVILLE, N.Y., Jul 17, 2002 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has agreed to accelerate the conclusion of the phase-out period of its funded research alliance with Anaderm Research Corp., a wholly owned subsidiary of Pfizer Inc.
OSI will receive an $8 million wind-down fee in consideration for transferring all research which is currently being performed by OSI to Anaderm. OSI will also receive royalties on treatments which may arise from compounds identified by OSI. As part of the original agreement, Anaderm will continue with the development of novel treatments for skin and hair conditions. The transfer is expected to be completed by the beginning of 2003.
"This agreement allows us to exit this area of research completely and continue our effort toward focusing the business on becoming a leading oncology franchise," stated Colin Goddard, Ph.D., Chairman and Chief Executive Officer of OSI. "As with our other former collaborations, OSI will receive royalties from Pfizer on treatments which may arise from compounds identified by OSI."
OSI functioned as the drug discovery and pre-clinical development arm of Anaderm, providing a full range of capabilities for the discovery of novel treatments for skin and hair conditions. These are pharmacologically active compounds for use in certain cosmetic and quality-of-life indications, such as skin pigmentation, skin wrinkling, and hair loss. To date, several compounds have been identified in the program.
OSI Pharmaceuticals is a leading biopharmaceutical company primarily focused on the discovery, development and commercialization of innovative products for the treatment of cancer. OSI has built a pipeline of discovery programs and drug candidates addressing major, unmet medical needs in cancer and selected opportunities, including diabetes, arising from its extensive drug discovery research programs that represent significant commercial opportunities outside of cancer. OSI's most advanced drug candidate, Tarceva(TM) (erlotinib HCl, OSI-774), a small molecule inhibitor of the EGFR tyrosine kinase, is currently in Phase III clinical trials for lung and pancreatic cancers.
This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, uncertainties related to the identification of lead compounds, the successful pre-clinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies and other factors described on OSI Pharmaceuticals' filings with the Securities and Exchange Commission.
Additional information on OSI Pharmaceuticals is available at http://www.osip.com
CONTACT: OSI Pharmaceuticals Investor & Public Relations Kathy Galante, 631/962-2000 or Burns McClellan (representing OSI) Jonathan M. Nugent (Investors) Kathy Jones, Ph.D (Media) 212/213-0006 [/size][/size]
OSI Pharmaceuticals Concludes its Alliance with Anaderm and Pfizer; Continues to Focus on Oncology
MELVILLE, N.Y., Jul 17, 2002 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has agreed to accelerate the conclusion of the phase-out period of its funded research alliance with Anaderm Research Corp., a wholly owned subsidiary of Pfizer Inc.
OSI will receive an $8 million wind-down fee in consideration for transferring all research which is currently being performed by OSI to Anaderm. OSI will also receive royalties on treatments which may arise from compounds identified by OSI. As part of the original agreement, Anaderm will continue with the development of novel treatments for skin and hair conditions. The transfer is expected to be completed by the beginning of 2003.
"This agreement allows us to exit this area of research completely and continue our effort toward focusing the business on becoming a leading oncology franchise," stated Colin Goddard, Ph.D., Chairman and Chief Executive Officer of OSI. "As with our other former collaborations, OSI will receive royalties from Pfizer on treatments which may arise from compounds identified by OSI."
OSI functioned as the drug discovery and pre-clinical development arm of Anaderm, providing a full range of capabilities for the discovery of novel treatments for skin and hair conditions. These are pharmacologically active compounds for use in certain cosmetic and quality-of-life indications, such as skin pigmentation, skin wrinkling, and hair loss. To date, several compounds have been identified in the program.
OSI Pharmaceuticals is a leading biopharmaceutical company primarily focused on the discovery, development and commercialization of innovative products for the treatment of cancer. OSI has built a pipeline of discovery programs and drug candidates addressing major, unmet medical needs in cancer and selected opportunities, including diabetes, arising from its extensive drug discovery research programs that represent significant commercial opportunities outside of cancer. OSI's most advanced drug candidate, Tarceva(TM) (erlotinib HCl, OSI-774), a small molecule inhibitor of the EGFR tyrosine kinase, is currently in Phase III clinical trials for lung and pancreatic cancers.
This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, uncertainties related to the identification of lead compounds, the successful pre-clinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies and other factors described on OSI Pharmaceuticals' filings with the Securities and Exchange Commission.
Additional information on OSI Pharmaceuticals is available at http://www.osip.com
CONTACT: OSI Pharmaceuticals Investor & Public Relations Kathy Galante, 631/962-2000 or Burns McClellan (representing OSI) Jonathan M. Nugent (Investors) Kathy Jones, Ph.D (Media) 212/213-0006 [/size][/size]
Why would they not reveal information about the drug - on the clinical trial page it says that stuff like the name of drug, mechanism, etc were kept secret. Usually drug companies release all available information they have, even when the drugs are preclinical and especially when they are in phase 2-3. It doesn't make sense that they are keeping it a secret to keep some kind of competitive advantage, unless it competes with propecia...are there any other reasons for secrecy? Actually, I wasn't even aware that companies were ALLOWED to keep clinical trial data secret - otherwise it seems like companies developing new drugs that compete with existing drugs would routinely do this. Anyone more familiar with the whole approval process?
seekinghair
Member
- Reaction score
- 0
1) This is an old article about Anderm´s research:
Cosmetic drugs could clear up skin-deep fears of aging
By Steve Sternberg, USA TODAY
The folks who snapped the male world to attention with v**** are racing to produce the world's first "cosmeceuticals" - drugs designed specifically to fight liver spots, hair loss and wrinkles.
The scientists, financed by New York-based Pfizer, are inventing a whole field of research by applying the most powerful new tools of biological science to the old bugaboos of unsightly blemishes, baldness and sun-damaged skin.
In a year, they plan to begin the first human trials of a topical ointment that blocks the biological process that leads to liver spots. One or two years later, they hope to begin similar trials of a compound that switches on the scalp's hair-making machinery and another that smoothes out wrinkles.
"We're taking modern drug discovery technology and applying it to cosmetics," says Colin Goddard, the chief executive officer of OSI Pharmaceuticals in Uniondale, N.Y.
Last week, OSI announced it will get a six-year infusion of $50 million from Pfizer, maker of the impotence drug v****, to back the venture.
"The really quite interesting aspect of this is that it is a new area of endeavor for the pharmaceuticals industry," Goddard says.
"We think quality-of-life products will be very important and financially rewarding into the next century. We think these products will be worth hundreds of millions of dollars - even billions of dollars - in the marketplace."
Goddard says the demand will come from the baby boomers who made v**** so successful. It was v****'s success, he says, that prompted Pfizer "to explore something that's entrepreneurial and out of the mainstream."
Pfizer three years ago formed a "virtual" company, Anaderm Research, to serve as an umbrella for executives from Pfizer, OSI and four skin experts from New York University, who contribute ideas and research expertise to the venture.
Goddard and NYU's Irwin Freedberg, the university's chairman of dermatology and a limited partner in the venture, declined to discuss specifics of the experimental compounds, fearing that they would tip off competitors.
But they disclosed generally how they might work.
For instance, they say, it is well known how the skin makes the pigment melanin. The challenge is to develop an ointment that can be absorbed into the skin and interrupt the biochemical cascade that deposits excess melanin in the skin, forming liver spots.
OSI is attempting to winnow its roster of candidate compounds to the one that works the best.
When this process is complete, the company will apply to the Food and Drug Administration for permission to conduct human trials.
As for hair loss, Goddard and Freedberg say, new genetic techniques have begun to shed light on hair growth mechanisms.
It appears, Freedberg says, that balding men and women retain their ability to make hair, though the genetic mechanism for making hair follicles is turned off. The challenge is to find a way to switch these genes back on, and the researchers say they are well on their way to finding one.
2) And this is Freedberg´s last publication apparently funded by Anaderm!!!
The Journal of Investigative Dermatology
Volume 125 Issue 1 Page 24 - July 2005
doi:10.1111/j.0022-202X.2005.23746.x
Expression of an Olfactomedin-Related Gene in Rat Hair Follicular Papilla Cells
Qiong Cao*1, Dawen Yu*, Andy Lee*, Yuko Kasai*†, Birte Tychsen‡, Ralf Paus‡, Irwin M. Freedberg* and Tung-Tien Sun*§
Follicular papilla (FP) cells, but not their closely related dermal fibroblasts, can maintain hair growth suggesting cell type-specific molecular signals. To define the molecular differences between these two cell types, we generated a subtraction complementary DNA (cDNA) library highly enriched in FP-specific cDNA. Differential screening identified FP-1 as the most abundant cDNA sequence in this subtraction library. FP-1 message RNA is highly abundant in cultured rat vibrissa FP cells, can be detected at very low levels in the stomach and the ovary, and is undetectable in cultured dermal fibroblasts and in 16 rat non-follicular tissues. The full-length, 2.3 kb FP-1 cDNA encodes a protein of 549 amino acids harboring a signal peptide, collagen triple helix repeats, and an olfactomedin-like domain. Monospecific rabbit antibodies to FP-1 recognize in cultured FP cells a single 72 kDa glycoprotein with a 60 kDa protein core. FP-1 protein is expressed in vivo in a hair cycle-dependent manner, as it can be detected in FP during anagen, but not in catagen and telogen phases of the hair cycle. FP-1 is presumably a highly specific extracellular matrix protein synthesized by FP cells and may be involved in the organization of FP during certain phases of normal or pathological hair growth.
Cosmetic drugs could clear up skin-deep fears of aging
By Steve Sternberg, USA TODAY
The folks who snapped the male world to attention with v**** are racing to produce the world's first "cosmeceuticals" - drugs designed specifically to fight liver spots, hair loss and wrinkles.
The scientists, financed by New York-based Pfizer, are inventing a whole field of research by applying the most powerful new tools of biological science to the old bugaboos of unsightly blemishes, baldness and sun-damaged skin.
In a year, they plan to begin the first human trials of a topical ointment that blocks the biological process that leads to liver spots. One or two years later, they hope to begin similar trials of a compound that switches on the scalp's hair-making machinery and another that smoothes out wrinkles.
"We're taking modern drug discovery technology and applying it to cosmetics," says Colin Goddard, the chief executive officer of OSI Pharmaceuticals in Uniondale, N.Y.
Last week, OSI announced it will get a six-year infusion of $50 million from Pfizer, maker of the impotence drug v****, to back the venture.
"The really quite interesting aspect of this is that it is a new area of endeavor for the pharmaceuticals industry," Goddard says.
"We think quality-of-life products will be very important and financially rewarding into the next century. We think these products will be worth hundreds of millions of dollars - even billions of dollars - in the marketplace."
Goddard says the demand will come from the baby boomers who made v**** so successful. It was v****'s success, he says, that prompted Pfizer "to explore something that's entrepreneurial and out of the mainstream."
Pfizer three years ago formed a "virtual" company, Anaderm Research, to serve as an umbrella for executives from Pfizer, OSI and four skin experts from New York University, who contribute ideas and research expertise to the venture.
Goddard and NYU's Irwin Freedberg, the university's chairman of dermatology and a limited partner in the venture, declined to discuss specifics of the experimental compounds, fearing that they would tip off competitors.
But they disclosed generally how they might work.
For instance, they say, it is well known how the skin makes the pigment melanin. The challenge is to develop an ointment that can be absorbed into the skin and interrupt the biochemical cascade that deposits excess melanin in the skin, forming liver spots.
OSI is attempting to winnow its roster of candidate compounds to the one that works the best.
When this process is complete, the company will apply to the Food and Drug Administration for permission to conduct human trials.
As for hair loss, Goddard and Freedberg say, new genetic techniques have begun to shed light on hair growth mechanisms.
It appears, Freedberg says, that balding men and women retain their ability to make hair, though the genetic mechanism for making hair follicles is turned off. The challenge is to find a way to switch these genes back on, and the researchers say they are well on their way to finding one.
2) And this is Freedberg´s last publication apparently funded by Anaderm!!!
The Journal of Investigative Dermatology
Volume 125 Issue 1 Page 24 - July 2005
doi:10.1111/j.0022-202X.2005.23746.x
Expression of an Olfactomedin-Related Gene in Rat Hair Follicular Papilla Cells
Qiong Cao*1, Dawen Yu*, Andy Lee*, Yuko Kasai*†, Birte Tychsen‡, Ralf Paus‡, Irwin M. Freedberg* and Tung-Tien Sun*§
Follicular papilla (FP) cells, but not their closely related dermal fibroblasts, can maintain hair growth suggesting cell type-specific molecular signals. To define the molecular differences between these two cell types, we generated a subtraction complementary DNA (cDNA) library highly enriched in FP-specific cDNA. Differential screening identified FP-1 as the most abundant cDNA sequence in this subtraction library. FP-1 message RNA is highly abundant in cultured rat vibrissa FP cells, can be detected at very low levels in the stomach and the ovary, and is undetectable in cultured dermal fibroblasts and in 16 rat non-follicular tissues. The full-length, 2.3 kb FP-1 cDNA encodes a protein of 549 amino acids harboring a signal peptide, collagen triple helix repeats, and an olfactomedin-like domain. Monospecific rabbit antibodies to FP-1 recognize in cultured FP cells a single 72 kDa glycoprotein with a 60 kDa protein core. FP-1 protein is expressed in vivo in a hair cycle-dependent manner, as it can be detected in FP during anagen, but not in catagen and telogen phases of the hair cycle. FP-1 is presumably a highly specific extracellular matrix protein synthesized by FP cells and may be involved in the organization of FP during certain phases of normal or pathological hair growth.
G
Guest
Guest
Good post seekinghair, thanks! Especially Freedberg's study is very very interesting...
Pfizer might surprise us all very quickly!
Pfizer might surprise us all very quickly!